



BioRx Acquires Coagulife Pharmacy

July 9, 2012



BioRx, one of the nation's fastest growing providers of specialty pharmaceuticals and infusion services, has acquired Coagulife Pharmacy, based in Savage, Minnesota. Coagulife provides medications and supplies for the treatment of hemophilia and related bleeding disorders; its management team and employees have joined BioRx.

“The addition of Coagulife’s talents and expertise will contribute significantly to our leadership in home hemophilia care,” said Phil Rielly, CEO and co-founder of BioRx. “We are excited to grow together in delivering outstanding personalized care to the bleeding disorders community.”

Coagulife was founded in 2004 by brothers Jeff and Daniel Kallberg. Jeff lives with hemophilia and speaks nationally about the importance of physical activity for hemophilia patients. He is a licensed physical therapist and holds a black belt in tae kwon do. Building on Coagulife’s existing health and wellness program, BioRx will develop a national joint care and rehabilitative support program for patients with chronic joint damage or recovering from surgical procedures.

“We are truly excited to expand our reach and capabilities through this agreement,” said Kallberg. “BioRx is widely regarded as a patient-focused, community-oriented company, and that has been our mission as well. Together we’ll be able to provide hemophilia patients with enhanced homecare services that are unavailable anywhere else in the country.”

Further information on BioRx can be found at www.biorx.com. ■

About Symmetric Capital

Symmetric Capital, a private equity firm focused on profitable growth companies in the United States and Canada, invested in BioRx in 2010. With the flexibility to invest in either minority or majority ownership positions, Symmetric structures transactions that meet both the immediate and the longer-term objectives of owners and managers – all without changing a company’s entrepreneurial culture or introducing excessive debt that restricts growth. Since 1990, Symmetric’s principals have built dozens of successful, collaborative partnerships, beginning in each case with an equity investment to fund growth, shareholder liquidity, debt repayment, a management-led buyout or a strategic acquisition.

Symmetric targets companies with at least \$10 million in revenues and \$2 million in operating profits. Sectors of interest include business and financial services, healthcare, technology, software, education, and consumer and industrial products. With over \$200 million in committed capital under management, Symmetric typically invests \$5-25 million in each company. Larger transactions can be funded in partnership with our limited partners or with other co-investors. For more information on Symmetric, please visit www.symmetriccapital.com.